Clene Inc

-0.07 (-1.18%)
Regulatory, Other Pre-Announcement

Clene Inc Says Topline Data From A Phase 2 ALS Trial And Two Phase 2 Target Engagement Studies In MS And Parkinson's Disease Expected In H2 2021

Published: 03/29/2021 11:18 GMT
Clene Inc (CLNN) - Clene Inc. - Topline Data From a Phase 2 Als Trial and Two Phase 2 Target Engagement Studies in Ms and Parkinson's Disease Expected in 2h 2021.
Clene Inc. - Full Enrollment in Phase 3 Registrational Trial in Als Expected in Mid-2021.
Clene Inc. - Clene's Cash Totaled Approximately $59.3 Million As of December 31, 2020.
Clene Inc. - Expects That Its Cash As of December 31, 2020 Will Be Sufficient to Fund Its Operating Expenses Into Mid-2022.